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Background: The process of tumorigenesis in adrenal tumors that occur sporadically is 
obscure. However, incidentally discovered adrenal masses are frequently observed (estimated 
incidence is between 0.35-4.36% in the general population) and they raise serious diagnostic 
and therapeutic problems. The percentage of bilateral tumors among adrenal incidentalomas is 
between 9-15%, and this high prevalence of bilateral tumors raise the possibility that systemic 
effects, such as genetic alterations, could play a role in their pathogenesis. The metabolic 
syndrome, hypertension, obesity and abnormalities of the hypothalamic-pituitary-adrenal 
(HPA) axis, such as lack of cortisol suppression after dexamethasone administration are more 
common in patients with incidentally discovered adrenal adenomas than in healthy 
individuals.  
Another important aspect of adrenal adenomas is its association with complex 
hormonal and metabolic profile which resembles to those observed in patients with 
glucocorticoid excess. Glucocorticoids produced in the adrenal cortex act by binding to a 
specific intracellular protein, the glucocorticoid receptor (GR), which in turn modulates 
transcription of genes containing a special sequence, the glucocorticoid responsive element 
(GRE).  Two isoforms of the GR were originally described; the functionally active GRα 
isoform encoded by exons 2–8 and part of exon 9 of the GR gene consists of 777 amino acids, 
and the GRß isoform in which the 50 amino acids at the C-terminal encoded by part of exon 9 
are replaced by 15 different amino acids encoded by part of the exon 9ß. It was earlier 
reported that the GRß isoform represents a potential endogenous inhibitor of glucocorticoid 
action in humans and its expression is increased in steroid resistant states and in patients with 
Cushing’s syndrome.  
The concentration of GR within each cell depends on several factors, including the cell 
type, cell cycle and stage of differentiation. In the absence of their ligands, the GR receptor 
remains sequestered in the cytoplasm through interactions with large multiprotein complexes 
containing heat shock proteins and cofactors. In our previous work we studied some aspects 
of the possible role of polymorphic GR gene variants in the pathophysiology of unilateral and 
bilateral adrenal incidentalomas. We found significantly higher carrier and allelic frequencies 
of the N363S variant of the GR in patients with bilateral incidentalomas compared to those 
with unilateral tumors or controls, which raised the possibility that an increased sensitivity to 
glucocorticoids reportedly present in N363S carriers may play a role in the development of 
bilateral adrenal tumors. Recently, it was reported that the GR is expressed in the human 
adrenal gland. In addition, nuclear cofactors are also involved in the modulation of gene 
expression during development, differentiation and endocrine therapies. Wang and co-workers 
using two different cell lines and cell-free pull-down and immunoprecipitation assays showed 
that nuclear receptor corepressor and silencing mediator of retinoid and thyroid hormone 
receptor associate with agonist and antagonist complexes of the GRs. It was suggested that the 
mutually antagonistic equilibrium interactions of corepressors and coactivators modulate the 
dose-response curve and partial agonist activity of the GR complexes. 
 
Aims and results 
1. Genetic variants of GR gene can be related to the adrenal tumorigenesis 
(Objective 1).  
For this specific aim we evaluated 134 patients with adrenal adenoma (102 with hormonally 
inactive adrenal adenoma: HI; and 32 with cortisol producing: CP tumor) and 129 healthy, 
Hungarian controls. Written informed consent form for genetic analysis will be collected. The 
molecular biological examination was performed using a Taqman allele-discrimination assay, 
on ABI7500 real-time PCR instrument. The carrier frequency of the N363S was higher in HI 
than in CP or healthy population, while the prevalence of A3669G (located in GRβ) was 
lower in patients with HI than in CP or controls (N363S: 7.4% vs 2,7% p<0.05; A3669G: 
14.7% vs. 22.1% p<0.05). These associations were even stronger in patients with bilateral HI 
tumors: N363S: 10.5% vs. 2.7% p<0.05; A3669G: 10.5% vs. 22.1% p<0.05) (Table 1). 
Similarly to N363S, the prevalence of haplotypes containing this variant was significantly 
higher in patients with HI than in controls or patients with CP especial in bilateral HI group 
(0,25 in bilateral HI vs. 0.05 in healthy or 0.03 in CP, p<0.05), while the prevalence of 
haplotypes containing A3669G was lower in HI than in controls or patients with CP (0.15 vs. 
0.34 or 0.34, p<0.05). The ER22/23EK was identified both in patients and controls together 
with A3669G. In CP group no associations between GR SNPs were observed.  
 
Table 1: Allele prevalence of GR polymorphisms among patients with adrenal incidentaloma 
and healthy individuals 
 GR polymorphisms Unilateral Bilateral Unilateral and bilateral healthy control 
BclI 0.22* 0.25 0.23* 0.34 
N363S 0,04 0.105** 0.07** 0.027 
A3669G 0.17 0.1** 0.14** 0.22 
ER22/23EK 0.03 0.07 0.03 0.08 
*p=0.011; **p<0,05 
 
Various genotype-phenotype associations have been observed:  
- the N363S polymorphism associated with type 2 diabetes mellitus  
- the polymorphism A3669G associated with higher body weight and body mass index 
- the BclI polymorphisms of the GR associated with higher systolic blood pressure and 
higher cholesterol level (Table 2) 
 
Table 2: Associations of GR polymorphisms with clinico-pathological and biochemical 
parameters in patietns with adrenal incidentalomas 
  
Wild Type 
(n=30) 
BCL 
(n=28) 
N363S 
(n=15) 
A3669G 
(n=23) 
BclI 
+A3669G 
(n=8) 
Serum cortisol 
Morning (08.00) 11.9 ± 6.6 10.8 ± 4.7 9.6 ± 3.7 10.7 ± 5 10.8 ± 6.8 
Night (24.00) 4.2± 4.4 4.4 ± 4.6 3.3 ± 1.9 4.3 ± 3.4 3.8 ± 2.6 
After ACTH 
stimulation 60.5 ± 29.8 63.5 ± 28.9 71 ± 35 56 ± 20 65 ± 46 
After LDD 1.9 ± 0.8 2.07 ± 1.1 2 ± 0.9 2.2 ± 1.6 2.3 ± 0.96 
ACTH      
Morning (08.00) 27 ± 16 36 ± 63 17 ± 6 18.1 ± 15 12.2 ± 10 
After metyrapon test 148 ± 132 346 ± 317* 168 ± 119 136 ± 143 172 ± 70 
DHEAS 84 ± 89 59 ± 44 82 ± 100 78.2 ± 148 140 ± 243 
Tumorsize (mm) 31 ± 19 27 ± 15 23.2 ± 12.6 26.9 ± 17 26 ± 20 
Blood pressure before surgery (Hgmm) 
systolic 134 ± 21 143 ± 21 144 ± 26 146 ± 23 144 ± 20 
diastolic  83 ± 7 86 ± 12 88 ± 14 89 ± 10 88 ± 11 
Total cholesterol 5.7 ± 0.8 6.3 ± 0.9 6.4 ± 1.7 6 ± 1.3 3.9 ± 1.2 
Serum triglyceride 1.6 ± 0.9 1.9 ± 1.2 2.2 ± 1.5 1.7 ± 0.9 1.2 ± 0.4 
Weight (kg) 72.1 ±14.5 85.1 ±  23.9* 79.7 ± 13.7 84.3 ± 15.7* 91.8 ± 17.7* 
BMI (kg/m2) 27.4 ± 5.7 31.2 ± 5.3* 31.1 ± 6.5 30.9 ± 4.3* 31.8 ± 3.4 
Prevalence of HT 0.77 0.75 0.64 0.76 0.71 
Prevalence of 
 T2DM 0.32 0.24 0.57* 0.38 0.42 
*: p<0,05 
 
Our results together suggest that the increased sensitivity against endogenous 
glucocorticoids can play a role in the pathogenesis of hormonally inactive adrenal 
incidentalomas especial in bilateral cases. In addition BclI, A3669G may contribute to the 
development of obesity in these patients, while the N363S represents susceptibility for type 2 
diabetes mellitus in this patient group. The abstract containing all these data have been 
submitted and accepted at the 92th Annual Meeting of the Endocrine Society, ENDO10, San 
Diego, USA, at the 23th Annual Meeting of the Hungarian Society of Endocrinology and 
Metabolism, Visegrad, Hungary and at Congress on Steroid Research in Chicago, 20111-3. 
Manuscript containing these data is in preparation, the deadline for its submission to The 
Journal of Steroid Biochemistry and Molecular Biology is August 1, 2011.  
 
2. The second objective was evaluation of the expression of the GR isoforms at mRNA 
and protein levels in different adrenal adenoma tissues. The GR, using an N-terminal 
antibody is expressed in normal human adrenal cortex, however, no data have been reported 
about the GR expression in pathologic adrenocortical tissues and about expression of specific 
isoforms of the GR. We examined the GRα and GRβ on mRNA level by quantitative real-
time PCR (qRT-PCR) in 31 adrenal tissues including 19 non-functioning adenomas (NFA), 6 
cortisol-producing adenomas (CPA) and 6 normal adrenocortical tissues, and on protein level 
by immunohistochemistry. First, we extracted RNA from fresh frozen adrenal tumor samples 
using Qiagen RNA extraction kit, following the manufacturer’s instruction. Reverse 
transcription and qRT-PCR measurements were performed using our Taqman assays. The 
specificity of primers and probes were demonstrated by gel electrophoresis and by direct 
DNA sequencing (Figure 1., Panel A). 
 
Figure 1: Panel A: Gel electrophoresis of 
quantitative RT-PCR amplicons of Grα 
and GRβ showing a single specific band 
for both Grα and GRβ in CPA and normal 
adrenal tissue (N). Panel B: Western blot 
analysis of GRβ and β-actin in CPA and 
normal adrenal tissue (N) illustrating a 
strong signal of 90 kDa in CPA and the 
absence of specific signal in normal 
adrenal tissue (N). L: DNA ladder.   
 
 
In order to detect the GRβ isoform on protein level we needed to examine the specificity of 
the anti-GRβ antibody. We performed Western blot analysis of total protein extracts of 
adrenal samples. GRβ protein was detected by immunoblotting with GRβ antibody (GRß, 
Abcam 3581, dilution: 1:1000, Abcam plc, Cambridge, UK) followed by incubation with goat 
anti-rabbit horseradish peroxidase-conjugated secondary antibody (sc-2004; dilution 1:7000) 
(Santa Cruz Biotechnology, Santa Cruz, USA) (Figure 1. Panel B). Compared to normal 
adrenocortical tissues, both GRα and GRβ mRNAs were significantly increased in CPA 
whereas GRα, but not GRβ mRNA expression was moderately increased in NFA. Using anti-
GRα antibody a strong nuclear staining was observed in NFA and CPA, and a less remarkable 
immunoreactivity was detected in some nuclei of normal adrenocortical cells (Figure 2). GRβ 
immunostaining was absent in normal adrenal tissues and NFA, while a strong cytoplasmic 
and nuclear immunoreaction was found in CPA. These data together may indicate that the 
altered expression of GRα and GRβ in CPA and that of GRα in NFA raises their possible role 
in the pathophysiology of these adrenal tumors 3. 
 
Figure 2. Immunohistochemical detection of GRα (A-C) and GRβ (D-F) in human 
adrenocortical tissues (magnification 400x). A and D, normal adrenocortical tissues; B and E, 
non-functioning adrenocortical adenomas; C and F, cortisol-producing adrenocortical 
adenomas.  Arrows show nuclear staining for Grα in some normal adrenocortical cells (Boyle 
et al, Steroids. 2010 Oct;75(10):695-700)  
In addition a strong correlation was observed between the expression of GRα and GRβ in 
hormonally inactive and cortisol-producing adrenal adenomas (Figure 3), which may suggest 
that the expression of the GR isoforms are regulated by a common promoter. 
 
Figure 3: Correlation between mRNA expression of GRα and GRβ in hormonally inactive 
adrenal adenomas (left panel) and in cortisol producing tumors (right panel). (Boyle et al, 
Steroids. 2010 Oct;75(10):695-700) 
 
 
 
Objective 3. Evaluation of the expression of nuclear cofactors at mRNA level in different 
adrenal adenoma tissues (3a); and in in vitro models of glucocorticoid action (3b). 
 
Many aspects of the GR related gene regulation machinery complex are poorly understood. 
Our proposal aims to evaluate systematically the role of the GR and other nuclear cofactors 
and corepressors in the pathogenesis of different adrenal tumors.  Using custom designed gene 
expression array (TLDA: Taqman Low-density Array) we analyzed the expression level of 94 
different genes in normal and pathological adrenal tissues. To date, we have collected a total 
of 48 adrenal tissue specimens (10 normal-N, 12 CPA, 23 HI and 3 adrenocortical 
carcinomas). RNA extraction and gene expression analysis were performed in 12 samples (5 
CPA, 4 HI and 3N). Statistically significant differences were observed between CPA and N 
samples, and these genes were also upregulated after treatment of H295R human 
adrenocortical cells with dexamethasone (100nm), suggesting that these alterations are related 
to the increased concentration of glucocorticoids in the adrenal gland (Objective 3b)6.  
 
3a: Using custom designed gene expression array (TLDA; Taqman low density array) we 
analyzed the expression level of 94 different genes including 47 nuclear receptors, 12 nuclear 
receptor coactivators and 4 endogenous controls in normal and pathological adrenal tissues. 
Adrenocortical tumor tissues were obtained from 17 patients undergoing adrenalectomy, 
including 11 patients with hormonally inactive adrenal adenoma (HI; 10 females, one male, 
median age at the time of diagnosis: 41.8±10.5 years) and 6 patients with Cushing’s syndrome 
due to cortisol-producing adrenal adenoma (CPA; 5 females and one male, median age at the 
time of diagnosis: 49±9.3 years). In addition 6 normal adrenal were also examined. We found 
2 genes showing significant decreased expression in CPA compared to normal tissue, one 
gene (RARB) showing significantly decreased expression in HI compared to normal tissue 
and another one (NR0B1) showing overexpression in CPA compared to normal adrenal gland 
(Table 3). 
  
Genes showing 
significant 
alteration 
CPA vs. normal adrenal tissue HI vs. healthy adrenal tissue 
fold change p fold change p 
HSP90B1 0.478 0.033 0.64  NS  
NR2F1 0.440 0.044 0.55 NS 
RARB 0.363 NS 0.362 0.047 
NR0B1  2.71  NS 1,01   NS 
 
3b: Using the same experimental TLDA platform we examined the expression of nuclear 
cofactors in H295R human adrenocortical cell line before and after dexamethasone treatment 
in order to mimic conditions observed in CPA. We identified 17 nuclear cofactors and 
corepressors significantly altered by Dex treatment. Of particularly interesting genes 
HSP90B1, RARB and NR0B1 significantly changed after Dex treatment and correlated with 
cortisol level secreted by these cells into the maintaining media. However, expression of the 
NR2F1 showed just a tendency suggesting that this cofactor may not be related directly to the 
glucocorticoid receptor (GR) mediated effect.  
From these preliminary data we may conclude that nuclear coactivators and corepressors may 
be involved in the pathogenesis of adrenal adenomas, mainly in hormone-secreting tumors, 
but further studies warranted for clarification of their role. One particularly interested factor, 
NR2F1 (COUP-TFI: transcription factor coup I, EAR3: ERBA related 3) has been identified 
as a potential GR-independent factor which downregulation may account for 
adenomatogenesis of CPA. NR2F1 is an orphan receptor, contains a DNA-binding and a 
putative ligand-binding domain. In the mouse, COUP-TFI and COUP-TFII (Nr2f1 and Nr2f2) 
are essential for early neural development and organogenesis, several genes has been 
validated as COUP-TFI targets: Fabp7, Crabp1, Sod1 Casq1-, Foxo3a. Its potential role in 
adrenal tumorigenesis needs further studies. These results were presented at two scientific 
meetings and the manuscript containing our preliminary data is in preparation5,6. 
 
Objective 4: Identification of specific genes differentially regulated by the two isoforms 
of the GR.  
For this specific aim we need a model which contains this isoform. Therefore, we started to 
make a cell line which stably expresses the GRß isoform. GR receptor isoforms were cloned 
from HeLa cells by two-steps RT-PCR. The first product corresponded to common 5’ α and β 
fragment ending at the ligand binding domain (LBD). The second fragment was the LBD 
domain of the GRα isoform. The fragments generated in the first two RT-PCRs were used as 
template for the second PCR amplification that resulted in the full length (2600bp) PCR 
product of the GRα. To generate the DNA fragment corresponding to the β isoform PCR 
reaction was performed, using the α isoform as a template. The sense primer corresponded to 
the common GRα/GRβ starting point of the LBD domain, and a 67 bp-long antisense primer 
containing a 19 bp-long sequence, which is the last common sequence in the α and β forms, 
and a 48 bp-long β specific sequence, which contains the full length of the β isoform specific 
sequence. The reaction resulted in a 711 bp-long PCR product (Fig.5).  
Figure 5. PCR products of α and β isoforms 
of the human glucocorticoid 
receptor
GR α mRNA
2600 bp
1046 bp
1825 bp
GR β LBD
711 bp GR β LBD
 
The PCR fragments coding the different GR isoforms were cloned into the eukaryotic 
expression vector pcDNA3.1/V5-His-TOPO. The completed constructions were verified by 
direct DNA sequencing.  Transfection of Caco cells was performed using Lipofectamine2000 
transfection reagent. The clonal selection was performed using neomycin antibiotic (500 
µmol/ml). The expression of the GRβ on mRNA level was detected by RT-PCR, with the 
same primers as were used for qRT-PCR experiments performed in adrenal tissue. The GRß 
content of Caco-2-GRß cells were quantified by quantitative real-time PCR using Taqman 
assays. In our Caco-2GR model the GRα/GRβ ratio varied between 1:1-0,4 (clone5-clone23) 
which all were significantly higher of that measured in wild type Caco-2 where this ratio is: 
1:0,001 (Figure 6). 
 
Figure 6: Ratio between the expression 
levels of the Grα and GRβ isoforms in 
basic Caco-2 and in Caco-2-Grβ clones. 
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Both the basic Caco-2 and Caco-2-GRß cell lines were treated with Dexamethasone (Dex, 100 
nmol) for 8 h. After Dex treatment cells were harvested and total RNA was isolated. A whole 
genome gene expression array was performed by Agilent 44K microarray.  Microarray data 
analysis revealed that 1156 transcripts (978 genes) were differentially expressed in Caco-2-
GRß cells compared to the basic Caco-2 cell line. Of these, 228 were underexpressed and 750 
overexpressed. We validated these microarray data with individual Taqman gene expression 
assays. Totally, 61 genes were included into validation experiment. Of these, 51 showed the 
same expression pattern as was detected by microarray, demonstrating that the specificity of 
the microarray gene expression analysis is 82% (Figure 7).  
 
Figure 7: Correlation between gene 
expression measured by microarray and 
individual Taqmn assays. 
 
The global gene expression profile indicated that the Caco-2GRβ cell line behaves like the 
Dex treated Caco-2 cell line, the global gene expression profile of both under and 
overexpressed genes has been shifted, hence suggesting that the GRβ isoform contribute to the 
glucocorticoid resistance in this cell line (Figure 8). 
 
Figure 8: Gene expression change after 
dexamethasone treatment in Caco-2 and 
Caco-2-GRβ cell lines. Expression profile 
of dex-treated Caco-2 cell line was similar 
to those observed in basic condition of 
Caco-2-GRβ clone. In addition similar 
genes were altered in both cell lines, just a 
shift in expression profile was observed in 
Caco-2-GRβ clone compared to Caco-2. 
 
 
Of the significantly overexpressed genes we identified genes which are involved in regulation 
of apoptosis (Bcl2, Casp1), metabolism (CPE, NNMT, Large, PAH, SLC26A9), immune and 
inflammatory response (IL1RAP, SAMD9, DEFB1), signal transduction (RHOBTB1, RICH2, 
TGFB2), gene transcription and/or RNA processing regulators (RBMS3, SATB1)  and genes 
encoding matrix proteins (VIM, CDH6, SPP1, SPARC, COL4A6).  
Among genes with reduced expression in Caco-2-GRß cells compared to the basic 
Caco-2 cell line genes involved in immune response (CXCL1, CXCL2, CXCL3), in gene 
transcription (NFIA, RPL39L), metabolism (PDE4A), cell signaling (SAMD1, S100P, 
SSTR1) have been identified. Gene set enrichment analysis (GSEA) with highly significant 
prediction showed that in Caco-2GRβ an inhibition of genes containing consensus site for 
E2F1 transcription factor, and an overexpression of genes containing consensus site for 
androgen receptor (AR) and GR, respectively. These results together may suggest that the 
GRβ isoform may forms a heterodimer not only with GRα but also with E2F1 and/or AR. In 
addition in basic Caco-2 cell line the GSEA analysis confirmed the previous findings that the 
dex treatment contributes to downregulation of genes containing consensus site for AP1 and 
CREB binding sites. 
Caco-2 cell line is an ideal model for studying the pathomechanism of inflammatory 
bowel disease including diseases: Crohn disease and colitis ulcerosa. We evaluated using 
bioinformatical approaches the expression profiles of samples obtained from patients 
suffering from colitis ulcerosa and Crohn disease submitted to gene expression omnibus in 
order to correlate our experimental data to those obtained from patients. Our analysis revealed 
that expression of 90 genes were both included in Caco-2-GRβ versus Caco-2 and Crohn 
disease versus normal mucosa comparisons and 100 genes were common in Caco-2-GRβ 
versus Caco-2 and Colitis ulcerosa versus normal mucosa comparisons. Further analysis of 
patient samples we found that according to the treatment status in Crohn disease group we 
found 10 genes which were differentially expressed in responders to treatment compared to 
non-responders and also these 10 were found as regulated by GRβ. Similarly, in colitis group 
we identified 5 such genes.    
These result need to be confirmed, therefore we plan to further study the relevance of 
our findings, but these results present starting point for identification of novel biomarkers for 
prediction of treatment success in patients with inflammatory bowel disease, and also 
potential novel therapeutic targets in this disease. 
 
 
